You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Namepimagedine HCl
Accession NumberDB05383
TypeSmall Molecule
GroupsInvestigational
Description

It has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease.Pimagedine HCl is an advanced glycation end products inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.

Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
UNIIA2Z7G2RGAH
CAS numberNot Available
WeightAverage: 110.546
Monoisotopic: 110.035923951
Chemical FormulaCH7ClN4
InChI KeyInChIKey=UBDZFAGVPPMTIT-UHFFFAOYSA-N
InChI
InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H
IUPAC Name
2-azaniumylguanidine chloride
SMILES
[Cl-].NC(N)=N[NH3+]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as guanidines. These are compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassGuanidines
Sub ClassNot Available
Direct ParentGuanidines
Alternative Parents
Substituents
  • Guanidine
  • Hydrocarbon derivative
  • Organic chloride salt
  • Organic salt
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in diabetic kidney disease.
PharmacodynamicsNot Available
Mechanism of actionPimagedine reportedly inhibits the formation of glycosylated proteins (advanced glycosylation end-products) and has other actions including inhibition of aldose reductase.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.692
Blood Brain Barrier+0.856
Caco-2 permeable-0.5175
P-glycoprotein substrateNon-substrate0.7868
P-glycoprotein inhibitor INon-inhibitor0.9741
P-glycoprotein inhibitor IINon-inhibitor0.987
Renal organic cation transporterNon-inhibitor0.8328
CYP450 2C9 substrateNon-substrate0.8715
CYP450 2D6 substrateNon-substrate0.8173
CYP450 3A4 substrateNon-substrate0.7739
CYP450 1A2 substrateNon-inhibitor0.7712
CYP450 2C9 inhibitorNon-inhibitor0.8703
CYP450 2D6 inhibitorNon-inhibitor0.8797
CYP450 2C19 inhibitorNon-inhibitor0.9132
CYP450 3A4 inhibitorNon-inhibitor0.8953
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.972
Ames testNon AMES toxic0.5
CarcinogenicityCarcinogens 0.5054
BiodegradationNot ready biodegradable0.976
Rat acute toxicity2.6226 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9054
hERG inhibition (predictor II)Non-inhibitor0.9697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility32.8 mg/mLALOGPS
logP-1.7ALOGPS
logP-1.5ChemAxon
logS-0.53ALOGPS
pKa (Strongest Basic)10.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.04 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity30.16 m3·mol-1ChemAxon
Polarizability7.32 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Abdel-Rahman E, Bolton WK: Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs. 2002 Apr;11(4):565-74. [PubMed:11922864 ]
  2. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 1992 Jan;41(1):26-9. [PubMed:1727735 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Glyceraldehyde oxidoreductase activity
Specific Function:
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
Gene Name:
AKR1B1
Uniprot ID:
P15121
Molecular Weight:
35853.125 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protease binding
Specific Function:
Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. May form part of a tissue-specific acute response to remodeling stimuli. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15.
Gene Name:
TIMP3
Uniprot ID:
P35625
Molecular Weight:
24144.83 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:24 / Updated on August 17, 2016 12:24